Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Prostate Cancer Stocks Recent News

Date Stock Title
May 21 AMGN Amgen, Inc. (AMGN) ATS and the Approval of IMDELLTRA Conference - (Transcript)
May 20 AMGN Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
May 20 AMGN AstraZeneca, Amgen release mid-stage data on Tezspire for COPD
May 20 EXEL Exelixis reaches Cabometyx patent settlement with Cipla
May 20 EXEL Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
May 20 AMGN The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli Lilly's, Viking, Altimmune, Roche and Amgen
May 19 AMGN NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
May 19 AMGN Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
May 18 AMGN Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
May 17 AMGN 4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
May 17 AMGN Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
May 17 AEZS Aeterna Zentaris Finalizes Some Details for Ceapro Merger
May 17 AMGN Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
May 17 AMGN FDA approves Amgen drug for tough-to-treat form of lung cancer
May 17 AEZS Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
May 17 AMGN Amgen’s IMDELLTRA receives FDA approval for lung cancer treatment
May 16 AMGN FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
May 16 AMGN Amgen wins FDA nod for new lung cancer therapy
May 16 EDAP EDAP TMS (EDAP) Q1 2024 Earnings Call Transcript
May 16 AYTU Q3 2024 Aytu Biopharma Inc Earnings Call
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags